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Heart failure is characterized by the transition froman
initial compensatory response to decompensation,
which can be partially mimicked by transverse aortic
constriction (TAC) in rodent models. Numerous
signaling molecules have been shown to be part of
the compensatory program, but relatively little is
known about the transition to decompensation that
leads to heart failure. Here, we show that TAC
potently decreases the RBFox2 protein in the mouse
heart, and cardiac ablation of this critical splicing
regulator generates many phenotypes resembling
those associated with decompensation in the failing
heart. Global analysis reveals that RBFox2 regulates
splicing of many genes implicated in heart function
and disease. A subset of these genes undergoes
developmental regulation during postnatal heart re-
modeling, which is reversed in TAC-treated and
RBFox2 knockout mice. These findings suggest that
RBFox2 may be a critical stress sensor during pres-
sure overload-induced heart failure.
INTRODUCTION
The mammalian heart contains post-mitotic cardiomyocytes,
and pathological loss of these cells is the ultimate cause of heart
failure (Diwan and Dorn, 2007). Most forms of cardiomyopathy
are associated with initial cardiac hypertrophy, which has been
widely considered a compensatory program during pathological
conditions. However, hypertrophy per se is not a prerequisite for
heart failure, as it also occurs under physiological conditions
(e.g., exercise). Even under pathological conditions (i.e., hyper-
tension, myocardial infarction, or ischemia), hypertrophy can
be decoupled from functional compensation in various genetic
models (Hill et al., 2000). Instead, progression to heart failure is
linked to the so-called decompensation process, which leadsCellto myocardial insufficiency (Diwan and Dorn, 2007). The induc-
tion of several critical signaling pathways has been linked to
the compensatory program, some of which appear to also
contribute to decompensation (Marber et al., 2011). However,
relatively little is known about molecular events responsible for
the transition from compensation to decompensation. In fact,
global approaches have been applied to heart disease samples
from both humans and animals (Giudice et al., 2014; Kaynak
et al., 2003), but it remains unclear whether dysregulation of in-
dividual genes are a cause or consequence of heart failure.
The RBFox family of RNA-binding proteins has been impli-
cated in development and disease (Kuroyanagi, 2009). Mamma-
lian genomes encode three RBFox family members, all of which
show prevalent expression in the brain. RBFox1 (A2BP1) and
RBFox2 (RMB9 or Fxh) are known to play central roles in brain
development (Gehman et al., 2011, 2012), whereas RBFox3
(NeuN) is a well-established biomarker for mature neurons
(Kim et al., 2009). In addition, both RBFox1 and RBFox2 are ex-
pressed in the heart where RBFox2 is expressed from embryo to
adult and RBFox1 is induced in postnatal heart (Kalsotra et al.,
2008), contributing to heart development and function in zebra-
fish (Gallagher et al., 2011). Upregulation of RBFox1 has been
detected in the failing heart in humans (Kaynak et al., 2003),
whereas mutations in RBFox2 have been linked to various hu-
man diseases, including autism (Sebat et al., 2007) and cancer
(Venables et al., 2009). A more recent study demonstrated that
RBFox2, but not RBFox1, is required for myoblast fusion during
C2C12 cell differentiation (Singh et al., 2014), thus strongly impli-
cating RBFox2 in heart development and function in mammals.
At the molecular level, both RBFox1 and RBFox2 have been
extensively characterized as splicing regulators that recognize
the evolutionarily conserved UGCAUG motif in pre-mRNAs
(Zhang et al., 2008) and regulate alternative splicing in a posi-
tion-dependent manner (Yeo et al., 2009).
Here, we report that the RBFox2 protein is decreased in
response to transverse aortic constriction (TAC) in the mouse
heart, and cardiac-specific ablation ofRBFox2generates an array
of phenotypes resembling those in TAC-induced heart failure.
Global analysis reveals an extensive RBFox2-regulated splicingReports 10, 1521–1533, March 10, 2015 ª2015 The Authors 1521
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Figure 1. Essential Requirement for RBFox2 to Prevent Heart Failure
(A) Western blotting analysis of RBFox2 in sham- and TAC-treated mice after 5 weeks postsurgery. GADPH served as a loading control.
(B) Kaplan-Meier survival curves of sham and TAC littermate male mice.
(C) Conditional RBFox2 KO and generation of heart-specific KO by crossing with an Mlc2v-Cre transgenic mouse.
(D)Western blotting analysis of RBFox1 and RBFox2 inWT andRBFox2KO cardiomyocytes at three postnatal stages. Triplicate results were quantified relative to
WT, as indicated below each gel.
(E) Survival curves of WT and RBFox2 KO littermate mice in both sexes.program, which likely constitutes a key part of the developmental
program during postnatal heart remodeling, and, importantly,
both TAC treatment and RBFox2 ablation reverse this splicing
program.Thesefindingssuggest that diminishedRBFox2expres-
sion may be a key event during heart decompensation.
RESULTS
RBFox2 Is Functionally Linked to Pressure Overload-
Induced Heart Failure
RBFox2 shows prevalent expression throughout heart develop-
ment (Kalsotra et al., 2008), but its biological function in cardiac1522 Cell Reports 10, 1521–1533, March 10, 2015 ª2015 The Authormuscle and potential contribution to heart disease in mammals
have remained unexplored. We first tested whether RBFox2
expression might be perturbed in a TAC-induced heart failure
model. Strikingly, we found that RBFox2 protein was largely
diminished in the heart of livemice 5weeks after TAC (Figure 1A),
which resulted in 30% mortality (Figure 1B). These data sug-
gest that RBFox2 may function as a key sensor to cardiac stress
and its downregulation is linked to heart failure.
To determine whether RBFox2 has a potential to contribute to,
rather than be a functional consequence of, heart failure, we took
advantage of anRBFox2 conditional knockout (KO)mouse (Geh-
man et al., 2012). By crossing RBFox2f/f mice with anMlc2v-Cres
(active at E8.5) transgenic mouse (Chen et al., 1998), we ablated
the gene at the onset of cardiogenesis (Figure 1C). Mice with
different genotypes all gave live birth, indicating that, once the
cardiogenic program is launched, RBFox2 is not essential for
the remaining steps in organ formation throughout embryonic
development.
Western blotting showed that the RBFox2 protein was sub-
stantially reduced in isolated RBFox2/ cardiomyocytes at the
several postnatal stages we examined (Figure 1D). In compari-
son, RBFox1 was elevated to some extent in RBFox2/ hearts,
indicating a degree of functional compensation. However,
RBFox2 clearly has a unique functional requirement in the heart,
as less than 5%ofRBFox2-ablatedmice of both sexeswere able
to survive beyond 1 year (Figure 1E). These results establish an
essential function of RBFox2 in postnatal heart, and, importantly,
suggest that diminished RBFox2 may be functionally linked to
pressure overload-induced heart failure.
RBFox2 Ablation Causes Dilated Cardiomyopathy that
Leads to Heart Failure
By echocardiography, we recorded severe contraction defects
in RBFox2/ heart (Figures 2A and S1A), which is characterized
by a significant increase in both end-systolic and end-diastolic
left ventricular internal dimension (LVID-S and LVID-D), resulting
in progressive decrease in fractional shorteningwith age (Figures
2B and S1A). At week 5, both the gross morphology and struc-
ture of theRBFox2/ heart showed relatively minor defects (Fig-
ures 2C and S1B), but by 9 weeks the cardiac chamber began to
enlarge and the ventricular wall became thinner, and by 22weeks
the RBFox2/ heart developed typical dilated cardiomyopathy
(DCM) (Figure 2C). Intriguingly, the development of DCM in
RBFox2/mice was not accompanied by the advent of cardiac
hypertrophy, as indicated by heart/body ratios similar to wild-
type (WT) mice (Figure 2D) and by little increase in cell surface
area of cardiomyocytes isolated by enzymatic perfusion at
week 9 (Figure 2E). These observations imply that dysregulated
RBFox2 may selectively contribute to heart decompensation
without first inducing hypertrophy. H&E staining showed exten-
sive disconnection of cardiomyocytes and Trichrome staining re-
vealed increased fibrosis at week 9 and onward (Figures S1B,
2F, and 2G).
Next, we examined calcium-handling properties on isolated
RBFox2/ cardiomyocytes. High-resolution line-scan mode
confocal microcopy revealed weakened calcium transients (Fig-
ures 3A and 3B), resulting in impaired whole-cell twitch (Fig-
ure 3C), even though the sarcoplasmic reticulum (SR) content
remained unaltered (Figure S2A). The calcium-handling defect
also was reflected by a significant elevation of self-evoked cal-
cium sparks (Figures 3D and 3E), indicative of severe calcium
leak (Cheng and Lederer, 2008). To further establish the primary
effects, we used two independent small interfering RNAs
(siRNAs) to knock down RBFox2 on cultured neonatal cardio-
myocytes from WT mice (Figure S2B), and observed similar cal-
cium-handling defects (Figure S2C), including reduced transient
peak (Figure S2D), increased calcium sparks (Figure S2E), and
elevated spontaneous transient frequency (Figure S2F). These
results suggest a direct contribution of RBFox2 to excitation-
contraction (EC) coupling in cardiac muscle.CellRBFox2 Regulates a Large Splicing Program in Cardiac
Muscle
Given that RBFox2 is a well-established splicing regulator, we
next aimed to elucidate the mechanism underlying the observed
functional defects by profiling the splicing program perturbed
in RBFox2/ heart. We took advantage of the RNA annealing-
selection-ligation coupled with deep sequencing (RASL-seq)
platform developed in our lab (Zhou et al., 2012), which mea-
sures 3,884 annotated alternative splicing events in the mouse
genome, thus providing a sensitive and cost-effective means
to broadly survey RBFox2-regulated splicing. To distinguish be-
tween likely direct functional consequences and those addition-
ally altered by accumulating defects, we surveyed three specific
developmental stages at postnatal weeks 5, 9, and 18 in
triplicate (Figures 4A and S3A), which respectively represented
an initial stage that showed detectable but minimal pathology,
an intermediate stage associated with evident cardiac malfunc-
tion, and a late stage when KO mice began to die (see Figures 1
and 2).
We recorded a sufficient number of splicing changes (more
than ten counts with both isoforms, p < 0.05 among triplicate)
among 70% of total surveyed splicing events in both WT and
RBFox2/ hearts at all three stages (Figure S3B). In aggregate,
we detected a total of 709 splicing switching events in 624
genes, among which 346 events exhibited enhanced exon
skipping and 363 events displayed induced exon inclusion in
response to RBFox2 ablation (Figure 4A; Table S2). We noted
that the number of dysregulated splicing events was already
comparable to that identified by large-scale RNA sequencing
(RNA-seq) on RBFox2 siRNA-treated C2C12 cells (Singh et al.,
2014), even though our platform only surveys a set of annotated
splicing events. Interestingly, the number of altered splicing
events increased during DCMprogression: using a stringent cut-
off (>2-fold in ratio change in addition to p < 0.05), we identified
308 (43.4% of total), 390 (55.0%), and 437 (61.6%) altered
splicing events at weeks 5, 9, and 18, respectively (Figures 4B
and S3A; Table S2). Together, these findings reveal an extensive
splicing program regulated by RBFox2 in the mouse heart.
Context-Dependent RBFox2 Binding Is Responsible
for Early Induced Splicing Events
The splicing changes detected at week 5 are likely direct targets
because of minimal morphological and structural changes de-
tected at this stage. One effective way to identify direct RBFox2
targets is to determine RBFox2 binding events on induced alter-
native splicing events and link RBFox2 binding to functional con-
sequences based on its well-established position-dependent
effects. We therefore performed genome-wide analysis of
RBFox2-RNA interactions by crosslinking iummunoprecipitation
followed by deep sequencing (CLIP-seq) on primary cardiomyo-
cytes isolated fromWTmice. From 67million mapped reads and
after removing PCR products based on built-in barcodes, we ob-
tained15million CLIP-seq reads that were uniquely mapped to
the mouse genome (Figure S3C). Interestingly, 64.0% reads
were mapped to intergenic regions, indicating additional func-
tions of RBFox2 in the mouse genome, and 24.3% reads to
intron regions, consistent with its roles in regulated splicing (Fig-
ure 4C). The RBFox2 CLIP-seq reads were enriched with theReports 10, 1521–1533, March 10, 2015 ª2015 The Authors 1523
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Figure 2. General Heart Failure Phenotype Induced in RBFox2 KO Mice
(A) Examples of cardiac echocardiography of WT and RBFox2 KO mice acquired at 9 weeks of age.
(B) Key echocardiography parameters of WT and RBFox2 KOmice at different ages. The data in each group were collected from five to eight mice and expressed
as mean ± SEM. *p < 0.05; **p < 0.01.
(C) H&E staining of the coronal sections of WT and RBFox2 KO hearts at different ages.
(D) Size andmass of WT and RBFox2 KO hearts at 9 weeks of age. (Left) Side-by-side comparison betweenWT and KO hearts at 9 weeks. (Right) Statistics of the
heart-to-body weight ratio of WT and KO hearts. The data in each group were collected from three mice and expressed as mean ± SEM.
(E) Size of cardiomyocytes isolated from WT and RBFox2 KO hearts at 9 weeks of age. (Left) Transmission images of WT and RBFox2-deleted cardiomyocytes.
(Right) Statistics of the cell surface area ofWT and KO cardiomyocytes. The data in each groupwere based on the analysis of 23–25 cells from threemouse hearts
and expressed as mean ± SEM.
(F) Statistics of fibrosis from Trichrome-stainedWT orRBFox2 KO hearts at different developmental stages. The data in each group were based on the analysis of
five to six images from two mice and expressed as mean ± SEM. **p < 0.01.
(G) Trichrome staining for fibrosis and myofibril disorder in RBFox2 KO heart by 22 weeks. See also Figure S1.expected UGCAUGmotif (Figures 4C and S3D), which underlies
29% of 149,832 identified RBFox2 binding peaks (Figure 4C),
similar to our previous observation on embryonic stem cells
(Yeo et al., 2009).1524 Cell Reports 10, 1521–1533, March 10, 2015 ª2015 The AuthorNext, we linked the CLIP-seq data to regulated splicing events
detected by RASL-seq, and observed the expected positional
effects on significantly altered events detected at all three
stages, showing enhanced exon inclusion when RBFox2 bounds
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Figure 3. Defective EC Coupling in RBFox2 KO Cardiac Muscle
(A) Confocal images of intracellular calcium transients and contraction. Isolated cardiomyocytes fromWT and KOmice at 9 weeks of age were paced electrically
at 1.0 Hz. Lower row shows the traces of spatially averaged calcium transient (top) and the corresponding cell shortening (bottom).
(B and C) Statistics of calcium transient peak (DF/F0, which is defined as the ratio between the signal and baseline) and twitch amplitude (TA) in cardiomyocytes
from WT and KO mice at two different ages. The data were based on the analysis of 13–20 cells from three hearts and expressed as mean ± SEM. **p < 0.01.
(D) Confocal measurement of spontaneous calcium sparks in 9-week WT or KO cardiomyocytes at rest.
(E) Statistics of the frequency of calcium sparks in cardiomyocytes fromWT or KOmice at two different ages. The data were based on the analysis of 14–20 cells
from three hearts and expressed as mean ± SEM. **p < 0.01. See also Figure S2 on the results observed on RBFox2 siRNA-treated cardiomyocytes.upstream introns and stimulated exon skipping when RBFox2
bound downstream introns (Figure 4D). In contrast, we saw no
such correlation with the splicing responses additionally de-
tected at weeks 9 and 18 (Figure 4E). These data indicate that
the alternatively spliced genes recorded at week 5 are likely pri-
mary targets for RBFox2, whereas those additionally detected in
later stages are secondary responses to accumulating defects in
RBFox2/ heart.
Critical Splicing Changes Underlie Specific Functional
Defects in RBFox2 KO Mice
We previously demonstrated the robustness of the RASL-seq
platform in profiling alternative splicing (Zhou et al., 2012),
which we further confirmed by RT-PCR on a panel of altered
splicing events at three developmental ages and linked those
induced-splicing to specific RBFox2-binding events (Figures
5A–5D and S4). Specific genes chosen for validation were
based on their existing functional information on heart develop-
ment and/or disease. For example, Pdlim5 and Ldb3 are impor-
tant for maintaining the structural integrity of the contractile
apparatus in the heart (Cheng et al., 2010; Zheng et al.,
2009). RBFox2 bound multiple strong consensus motifs (red)
located in the upstream intronic regions as well as on the alter-
native Pdlim5 exon 5a, resulting in suppression of the alterna-
tive exon (Figure 5A). Near the alternative exon 11 in Ldb3,
RBFox2 bound both upstream and downstream intronic re-
gions (although these motifs were not evolutionarily conserved,
labeled yellow, indicating potential synergistic actions of otherCellRNA-binding proteins), with a net effect that led to exon skip-
ping in RBFox2/ heart (Figure 5B).
We further probed the protein levels by western blotting,
showing reciprocal increase in the exon 5a-containing L isoform
and decrease in the exon 5b-containing S isoform in the case of
Pdlim5 in response to RBFox2 KO (Figure 5E). Note that both
Pdlim5 and Ldb3 genes produced two alternatively polyadeny-
lated isoforms (L and S) in which the L isoform carried both alter-
natively spliced mRNA isoforms, and RBFox2 ablation induced
the smaller isoform at both the RNA and protein levels (Figures
5B and 5E). The protein levels of both PDLIM5-S and LDB3-S
were also progressively diminished, indicating accumulating ef-
fects in RBFox2/ heart (Figure 5E).
We similarly validated additional RBFox2-regulated genes at
week 5 and onward, including Abcc9 (an ATP-sensitive potas-
sium channel), Sorbs1 and Sorbs2 (both being SH3 domain-con-
taining signaling molecules), and Enah (involved in cytoskeleton
organization and remodeling), each of which showed specific
RBFox2-binding events at locations that are consistent with
the positional rule established for RBFox2-regulated splicing
(Figure S4). Importantly, these genes also have been previously
linked to DCM (Aguilar et al., 2011; Bienengraeber et al., 2004;
Gehmlich et al., 2007; Yung et al., 2004).
Critical Splicing Events Were Induced in Key
Transcription Factor Genes
We also observed a major impact of RBFox2 ablation on alter-
native splicing of the MEF family of transcription factors,Reports 10, 1521–1533, March 10, 2015 ª2015 The Authors 1525
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Figure 4. Primary and Accumulated Defects in Disease Progression
(A) The heatmap of the splicing profiling data by RASL-seq among three different disease stages. The data were sorted by the mean value of the three stages
groups analyzed. Green, induced inclusion; red, induced skipping. Genes that previously were linked to DCM are highlighted on the right.
(B) Number of >2-fold significant events among disease stages.
(C) The genomic distribution of RBFox2 CLIP-seq reads (top). The top enriched motif and the percentage of the motif on total CLIP peaks are shown (bottom).
(D and E) The RNA maps of RBFox2-binding and -splicing responses based on those with >2-fold change relative to WT consistently detected among all three
stages (D) versus changes detected only in mice at weeks 9 and 18 (E). See also Figure S3 and Table S2.causing the exclusion of the alternative exon 9 in Mef2a and
the alternative exon 7’ in Mef2d (Figures 5C and S4), similar
to a recent report in C2C12 cells (Singh et al., 2014). These
induced isoform switches previously have been shown to
affect their activities in transcription (Zhu et al., 2005), consis-
tent with widespread changes at gene expression levels in
RBFox2 siRNA-treated C2C12 cells (Singh et al., 2014). Inter-
estingly, while the alternative exon does not change the1526 Cell Reports 10, 1521–1533, March 10, 2015 ª2015 The Authorreading frame in both of these cases, we additionally detected
a major reduction of Mef2a protein (Figure 5F), indicating the
involvement of RBFox2 in additional layers of regulation. The
altered transcription program may thus account for accumu-
lating changes in alternative splicing during the development
of disease phenotype in RBFox2/ heart, as suggested for
the function of RBFox1 in the nervous system (Fogel et al.,
2012).s
From the global perspective, we found that RBFox2-binding
events are directly linked to induced alternative splicing events
at week 5 (Figure 5G). Importantly, via GO term analysis of all ex-
pressed genes detected by RNA-seq (data not shown) in the
mouse heart at the same developmental stage, we found that
direct RBFox2 target genes are enriched in cytoskeleton organi-
zation and transcription in biological processes (Figure 5H).
Together, these observations suggest that the RBFox2-regu-
lated splicing program may directly contribute to the develop-
ment of disease phenotype in RBFox2/ heart, and many sec-
ondary effects, especially those observed in late stages, may
result from induced splicing of key genes involved in transcrip-
tional and post-transcriptional controls in cardiac muscle.
Pressure Overloading and RBFox2 Ablation Induce a
Related Splicing Program
Because TAC-induced pressure overloading diminished
RBFox2, we next performed RASL-seq on sham and TAC-
treated hearts, identifying 199 significantly changed splicing
events (Figure S5A; Table S3). These data allowed us to compare
with the splicing program in RBFox2/ heart despite the fact
that the altered splicing events in TAC-treated hearts were
measured on mice at age 14 weeks (TAC treatment began at
week 9 and lasted for 5 weeks), while total RNAs were extracted
from RBFox2 KO mice at postnatal week 5 after deletion of the
gene in an early embryonic stage.We thus anticipated numerous
compound effects to generate unique spectra of splicing
changes on the two different animal models. Nonetheless,
comparing between 709 splicing switches in RBFox2/ heart
and 199 events in response to TAC surgery in adult mice, we
identified 76 shared events that showed an overall positive cor-
relation between the two experimental conditions (Figure 6A,
left; Table S3). Importantly, among these 76 overlapping events,
54 (71%) showed changes in the same directions (Figure 6A,
right). Thus, diminished RBFox2 expression appears to partially
contribute to TAC-induced splicing and heart failure.
Heart Modeling-Induced Splicing Events Are Reversed
in Failing Heart
Although the identified alternative splicing events in RBFox2/
or in TAC-treated hearts provide a rich resource for functional
dissection on the single-gene basis to understand the contribu-
tion of individual altered splicing events to specific cardiac
functions, the induced-splicing program as a whole is likely
responsible for the complex heart failure phenotype observed
on each animal model. Oneway to assess the global contribution
of RBFox2-regulated splicing to heart failure is to compare
the compendium of RBFox2 ablation- or TAC-induced splicing
events with the splicing program associated with postnatal heart
remodeling. This developmentally regulated process occurs in
the first month of a newborn mouse’s life, and is critical for
enhancing cardiac performance to meet the demand for
increasing workload. In fact, multiple reprogramming events
have been characterized at the level of transcription, such as
switches in the expression of a to b myosine heavy chain, fetal
to adult troponin I, and b to a tropomyosin (Muthuchamy et al.,
1993). Importantly, switches of these genes in the reverse direc-
tion are often associated with heart failure (Krenz and Robbins,Cell2004; Muthuchamy et al., 1998). We thus hypothesized that
the splicing program might also undergo critical reprogramming
during heart remodeling.
To test this hypothesis, we performed RASL-seq on five devel-
opmental points in the first month of newborn mice from day 1 to
day 28. Comparison between the two endpoints revealed 564
significant switches in alternative splicing (Figure S5B), consis-
tent with the previous report (Giudice et al., 2014), indicating
that heart remodeling in the mouse is also associated with
extensive reprogramming at regulated splicing levels, which
may collectively contribute to augmented heart performance.
Focusing on the 54 genes that showed significantly altered
splicing in the same directions between RBFox2/ and TAC-
treated hearts (Figure 6A), we found an overall negative correla-
tion between development-associated changes and those
induced by RBFox2 ablation (Figure 6B, left; Table S3). Among
these events, 36 (67%) showed changes in opposite directions
(Figure 6B, right), indicating a substantial contribution of
RBFox2-controlled splicing to heart remodeling.
Developmentally Regulated RBFox2 Target Genes
Provide Diverse Cardiac Functions
To better appreciate the developmentally regulated splicing pro-
gram relative to TAC-induced and RBFox2 ablation-triggered
splicing events, we displayed dynamic splicing changes in the
36 genes surveyed by RASL-seq at different developmental
stages or under various treatment conditions (Figure 6C, green
or red colors highlight induced inclusion or skipping of alternative
exons). We noted that the patterns are similar between mice at
day 28 and sham-operated mice at week 14, indicating that
those developmentally regulated splicing events had largely
completed after postnatal remodeling in the first month, and
the induced mRNA isoforms then remained relatively constant
in adulthood. In contrast, a large percentage of these develop-
mentally reprogrammed splicing events were reversed in
response to TAC treatment or RBFox2 ablation (Figure 6C).
This reversal strongly suggests that RBFox2-regulated splicing
events contribute to augmented heart performance in adult
mice.
Importantly, the majority of those developmentally regulated
RBFox2 target genes (red-labeled genes on the right side of Fig-
ure 6C) have been implicated previously in heart function and/or
disease. Among these genes, two (Epb4.1, which encodes for
protein 4.1R, and Atp5c1, which encodes for the ATP synthetase
g subunit F1g) have been characterized extensively as direct
targets for the RBFox family of splicing regulators, and RBFox-
mediated repression of the alternative exon in each case has
been shown to be critical for enhanced cardiac function (Haya-
kawa et al., 2002; Ponthier et al., 2006). Our data now indicate
that these genes are also developmentally repressed during
postnatal modeling, and become derepressed in response to
both TAC treatment and RBFox2 ablation. Two other genes
(Camk2g and Slc4a4) also have been reported to respond to
pressure overloading in the heart (Colomer et al., 2003; Yama-
moto et al., 2007).
Other genes that show strong developmental regulation
and reversal in TAC-treated and RBFox2-ablated mice
include those involved in (1) cytoskeleton organization: Ank1Reports 10, 1521–1533, March 10, 2015 ª2015 The Authors 1527
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mRNA isoforms of these genes remain to be functionally charac-
terized, it is likely that the reversal of these developmentally
regulated splicing programs may collectively contribute to heart
failure in TAC-treated and RBFox2 KO mice.
DISCUSSION
RBFox2 Controls a Large Splicing Program in the Heart
RBFox2 has emerged as a key tissue-specific regulator of alter-
native splicing in development and disease through recognizing
the conserved UGCAUGmotif in metazoans (Zhang et al., 2008).
In mammalian heart, RBFox2 is expressed in a relatively con-
stant fashion, in contrast to the dramatic induction of the related
RBFox1 protein after birth (Kalsotra et al., 2008), which may
together regulate and maintain a key splicing program function-
ally important for postnatal heart remodeling. Such a synergistic
function between RBFox1 and RBFox2 has been demonstrated
in zebrafish heart development (Gallagher et al., 2011). Intrigu-
ingly, RBFox2 appears to play a more important role than
RBFox1 in C2C12 cells (Singh et al., 2014), and the lethal pheno-
type observed in RBFox2-ablated mice clearly demonstrated its
unique contribution to cardiac function, which is consistent with
the large altered splicing program in RBFox2 KO cardiomyo-
cytes, despite the continuous presence of RBFox1.
It is interesting to note that RBFox2-ablated mice were rela-
tively morphologically normal until 5 weeks after birth, indicating
that RBFox2 is critical for heart performance. By splicing
profiling, we identified a large number of RBFox2 target genes
based on direct binding evidence and resultant RNA map that
shows the anticipated positional effects. Importantly, these
RBFox2 target genes provide diverse cardiac functions, ranging
from key components of the contractile apparatus to various ion
channels and signaling molecules critical for coupling between
excitation and contraction to genes involved in energy meta-
bolism, as highlighted in Figure 6D. The RBFox2-regulated
splicing program is likely further amplified via its immediate
target genes, which include the MEF family of muscle-specific
transcription factors and other critical splicing regulators (such
as Mbnl2), eventually causing mortality of RBFox2 KO mice.
RBFox2 May Serve as a Key Sensor to Stress Signaling
Our current targeting study is of physiological relevance because
of the link between diminished RBFox2 protein and pressure
overloading. This implicates RBFox2 as a key sensor to stress
signaling in the heart. Interestingly, its mRNA level appeared
unaltered, as evidenced by multiple probe signals in our RASL-
seq oligonucleotide pool that remained unchanged in TAC-
treated mice. This suggests that RBFox2 protein might be
downregulated via a post-translational mechanism(s), which is
the subject of future studies. SuchunalteredmRNAwould escape
the detection in previous gene expression profiling experiments
on animal models (Zhao et al., 2004) or human patient samples
(Kaynak et al., 2003). Unfortunately, such unstable protein
in TAC-treated mice discouraged us from further evaluating
RBFox2 reduction andTAC-inducedphenotypewith a transgene.
Although it is currently unclear about themechanismneeded to
trigger the reduction of RBFox2 protein in TAC-treated mice, the
proposed sensor function raises an intriguing possibility that1530 Cell Reports 10, 1521–1533, March 10, 2015 ª2015 The AuthorRBFox2 might be a key target in certain stress-signaling path-
ways. In fact, diverse signal transduction pathways have been
shown to accompany physiological heart modeling or patholog-
ical responses in failing heart (van Berlo et al., 2013). Therefore, it
will be an important topic for future studies to understand how
RBFox2 expression is diminished in response to a specific stress
signal(s). As itsmRNAappearedunaltered in TAC-treated heart, it
will be particularly interesting to determine whether RBFox2 is a
target for a pressure overload-induced microRNA (Reddy et al.,
2012). Proteasome-mediated degradation also remains a formal
possibility to be tested in future investigation.
RBFox2 Might Be a Key Component of Decompensation
in Failing Heart
Mammalian genomes encode for a large number of RNA-binding
proteins, which together control an extensive alternative splicing
program (Fu and Ares, 2014) in development and disease (Kalso-
tra and Cooper, 2011). Because alternative splicing often intro-
duces subtle changes in mRNA that may alter RNA stability
and/or function, it has remained a major challenge to infer func-
tional consequences among numerous altered splicing events in
a given cell type or biological system. Here, we took advantage
of postnatal heart remodeling, a well-known positive force for
augmentationof cardiac functions.Byprofiling splicing in this crit-
ical developmental window, we identified a set of alternative
splicing events that are switched in a monotonic fashion. Impor-
tantly, many of those events were reversed in response to TAC
treatment or RBFox2 ablation, thus consistent with comprised
cardiac function via such a regulated splicing program. This in-
cludes F1g (encoded by Atp5c1), one of the best biochemically
characterized RBFox2 target genes (Fukumura et al., 2007), and
splicing of this ATP synthetase gene is known to enhance energy
production in the mitochondria of cardiac muscle (Hayakawa
et al., 2002). Defects in this and other RBFox2 target genes may
thus collectively contribute to heart failure in RBFox2 KO mice.
Our functional study of RBFox2-regulated splicing on the
mouse model also provides critical insights into cardiac decom-
pensation, which is a key but poorly understood process during
heart failure. We found that RBFox2 ablation induced a failure
phenotypewithout first inducing cardiac hypertrophy, consistent
with other genetic models in which compensation and decom-
pensation appear decoupled (Diwan andDorn, 2007). Our obser-
vations, that TAC triggered a dramatic reduction in RBFox2
expression and both TAC andRBFox2 ablation produced related
disease phenotypes and regulated a set of key alternative
splicing events, strongly suggest that RBFox2 may be a key
component of cardiac decompensation. It will be of great inter-
est to determine in future studies whether the RBFox2 level could
be correlated to hypertension-induced cardiac malfunction in
humans.
EXPERIMENTAL PROCEDURES
All works on animals were performed according to the protocol (S99116)
approved by our institutional review board.
Transaortic Banding Surgery
Nine-week-old male littermate mice were subjected to pressure overload by
TAC surgery, as described previously (Guo et al., 2014). After 5 weekss
postsurgery, total protein and RNA were extracted from isolated cardiomyo-
cytes from sham and TAC-treated mice for western blotting, RASL-seq, and
RT-PCR.
Generation of RBFox2 Cardiac-Specific KO Mice
The construction of conditional RBFox2 KO mice has been described previ-
ously (Gehman et al., 2012). Crossing of the mice with the Mlc2v-Cre trans-
genic mouse and characterization of the mutant mice are detailed in the
Supplemental Experimental Procedures. Specific siRNAs used in the current
study are listed in Table S1.
Echocardiography and Calcium Imaging
Phenotypic and echocardiographic analyses of RBFox2-ablated heart were
performed according to Xu and Fu (2005), and details also are provided in
the Supplemental Experimental Procedures.
RASL-Seq Profiling, Data Analysis, and RT-PCR Validation
RASL-seq is designed to profile mRNA isoforms using pooled pairs of oligo-
nucleotides each flanked by a universal primer to target specific splice junc-
tions in spliced mRNAs, as previously described (Li et al., 2012), and are
detailed in the Supplemental Experimental Procedures. Significantly changed
splicing events at different developmental stages in RBFox2 KO mice over
WT are listed in Table S2, and those induced by TAC treatment over sham
operation and those altered during postnatal heart development are listed
in Table S3.
RBFox2 CLIP-Seq
RBFox2 CLIP-seq and construction of the RBFox2 RNA map were detailed
previously (Yeo et al., 2009). A rabbit polyclonal anti-RBFox2 antibody (Bethyl
Laboratories, A300-864A) was used to immunoprecipitate RBFox2-RNA com-
plexes from isolated cardiomyocytes of week 9 mice hearts. For detailed an-
alyses, see the data analysis in the Supplemental Experimental Procedures.
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